Shipping pollution, under the sea – and is the love song dying?
Hello and welcome to another edition of The Crunch!
This week's newsletter is going to be slightly different as the longlist for the 2024 Information Is Beautiful awards was released this week. We've trawled through the list to find our favourites.
Our colleagues in the UK have released two great stories from the ocean's depths. The first is an explainer about mining the seafloor with lots of lovely visuals.
This map gives you an idea of the scope of the issue:
We covered seafloor mining in the Pacific way back in 2021. Scientists were already warning that we could lose marine species – even before we knew anything about them.
The next story follows the 'shadow fleets' that seem to be attacking Europe's undersea internet cables, below.
This story is chock full of great interactive maps and animations. I am very jealous.
There is a lot of amazing work in the longlist to explore, so we really encourage you to dive in for yourself. Our gender pay gap explorer and One Big Chart on the disproportionate impact of family violence also made the cut.
But here are some of the projects that jumped out at us (please note these aren't exhaustive lists, and we're trying to avoid stories that have already appeared in this newsletter – hence no AFL mullets).
Shipping stuff around Africa emits a lot of pollution
I'm a sucker for an illustrated story, and this is yet another brilliant one from Reuters. It's also a great example of following a counterfactual – looking at increased emissions once ships had to avoid the Suez canal after Houthi militants started attacking commercial ships. The design is lovely, as is using the Status of Liberty as a comparison for emissions.
Some other favourites (in no particular order):
A deep dive into what's driving up burger prices (in Australia)
A gloriously illustrated history and explanation of ancient Chinese hanfu
Visualising the issue of not having enough clothes – an issue I can't really relate to, but I love how extra this is
The monochroming of America – someone should do this in Australia
How the worldview of artificial intelligence is created (in German)
Sign up to The Crunch
Our data journalists showcase the most important charts and dataviz from the Guardian and around the web, free every fortnight
after newsletter promotion
Is the love song dying?
This is typically excellent work by contributors to the Pudding, which follows the publication's formula of using data to tell a story that involves an 'aha!' moment. Here's the direct link and the IIB entry showcase.
I had a lot of trouble choosing only five entries for my picks, so here are five dot points loosely grouped into themes in no particular order:
This investigation into the hairstyles of people who get swooped by magpies – a natural hazard in Australia – is a) awesome and b) has a great chart made out of Lego and c) is extra amazing because it was done by an eight-year-old. I particularly loved this quote from Emma, who said: 'To show the survey results, I decided to use Lego to illustrate my data because I didn't know how to use Excel.'
Nice maps: a map of forest cover of New Zealand, and a map that was specifically designed to appeal to me as it combines whisky, Scottish author Iain Banks and nice cartography.
Things I liked but can't explain why: are socks really hard to knit, and five droughts that changed history.
Projects involving audio: heat chords: strains of stress, and an underground journey.
A series of good charts on last year, explaining why it was a year that shook the world.
This chart speaks for itself – the US tariff rate on aluminium and steel imported from Canada across one day (11 March).
Enjoying The Crunch? If you like what you see and think you might know someone else who would enjoy it, please forward this email or send them a link to the sign up page.
If you have a chart tip or technical issue viewing this newsletter, please reply to this email.
If you are a Guardian supporter and need assistance with regards to contributions and/or digital subscriptions, please email customer.help@guardian.co.uk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Herald Scotland
16 hours ago
- The Herald Scotland
Lord Sainsbury: Give Glasgow greater devolved powers
"A major challenge which government faces if it wants to increase Scotland's rate of growth is a way to find and support such clusters," he said. "All the evidence from other countries suggests that the only way to effectively support clusters is to do so at a city region level. Read more: "I appreciate in Scotland, unlike in England, metro mayors have not yet been introduced, but if you want to support high-tech clusters, this is something I think you should seriously consider, with Greater Glasgow being given powers similar to those devolved to Greater Manchester and the West Midlands." Lord Sainsbury was speaking at the Creating the Jobs of Tomorrow conference organised by Glasgow Chamber of Commerce, where he was introduced to the stage by former Labour chancellor and prime minister Gordon Brown. Mr Brown said growth and productivity have been perennial problems in the UK and Scotland, with innovation the key to boosting performance. A new study by economist Dan Turner, head of research at the Centre for Progressive Policy, has suggested this could unlock the creation of hundreds of thousands of high-value jobs. "There are huge sources of innovation and inventiveness in Scotland, just as has been traditional in our history," he said. "The question is can we turn that into scalable companies that stay in Scotland, invest in Scotland, create jobs in Scotland, and Dan's study suggests we could create 300,000 jobs in the next 10 years. "That's 300,000 well-paying jobs, 120,000 in the new industries, the spin-offs in terms of the service sector another 180,000 - that is a possibility if we invest in the infrastructure, the skills, and the development necessary to achieve that." Lord David Sainsbury (Image: Nate Cleary) Lord Sainsbury is a Labour peer and served as minister for science and innovation under Mr Brown and his prime ministerial predecessor, Tony Blair, between 1998 and 2006. He was appointed a life peer in 1997. Lord Sainsbury said there are new opportunities for employment and growth in sectors such as quantum computing, artificial intelligence and biotechnology. "There are economists that will argue that it is investment that is the engine of economic growth, but we have to realise today that capital flows easily around the world, and it flows as it has always done, to where the best investment opportunities are created by innovation," Lord Sainsbury said. "You can sit in London today and you can invest in Silicon Valley, you can invest in practically any country - until recently you could even invest in Chinese venture capital - because that is what modern communication enables you to do. That is why investment is not the real driver of the economy, it's innovation." Among the other speakers was Michael Spence, who won the Nobel Prize in Economics in 2001 for his work in the analysis of markets with information imbalances. Read more: "There are two things that [people] associate with Adam Smith correctly," Mr Spence said. "One the 'invisible hand', which is the market system is a reasonably efficient tool for decentralising and allocating resources. "That actually is not the most important thing that Adam Smith said, but it's the one that neo-conservatives remember because they elevate market systems to the status of a religion, rather than a way of accomplishing economic and social goals. The most important one for our purposes is specialisation. "Adam Smith meant specialisation within an economy, when of course everything that David Sainsbury talked about in the global economy is just the Adam Smith insight writ large, and of course it is the ultimate source of growth. "Without specialisation you don't get scale of spread your activity over too much territory, and you don't get innovation. You get nothing if everybody has to do everything. "The fundamental message I want to deliver today is that's still true, and that growth is fundamentally about specialisation and structural change."
Reuters
a day ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
Daily Mirror
2 days ago
- Daily Mirror
Fears newly-discovered coronavirus is 'one step away' from infecting humans
A team of researchers from Washington State University fear the newly-discovered HKU5-CoV-2 coronavirus found in China could mutate enough to cause a pandemic Scientists have warned that a newly-discovered coronavirus could lead to another pandemic. Researchers from Washington State University believe the HKU5-CoV-2 virus, found in China, is only one "small" step away from mutating. This in turn could allow it to infect humans and cause a widespread outbreak. Experts are on guard due to the pathogen's close relation to MERS, a life-threatening virus that kills around a third of people infected. Adding to the fear is that HKU5 was first recorded in bats by scientists from the Chinese lab where some say Covid originally came from in 2019, resulting in millions of deaths. The latest study was published in Nature Communications and looked at a lesser-known group of coronaviruses known as merbecoviruses, which includes HKU5 and MERS-CoV. In it, a team from the US looked at how the new pathogen interacts with human cells. Professor Michael Letko, a virologist at Washington State who co-led the study, said: "HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans." It was found that a small change in the virus' spike protein could mean that it attaches to human ACE2 cells, which are located in people's throats, mouths and noses. At the moment, the pathogen is only spreading in bats. However, scientists are concerned that unregulated wildlife trade in China increases the possibility of it eventually being transmitted to other species. 'Pseudoviruses' were created in the lab that include the HKU5 spike protein but are ultimately harmless and cannot replicate. These were then introduced to different types of cells, with some carrying bat ACE2 and others carrying human ACE2. In the experiments, the virus glowed green when it had entered and replicated inside a cell. The bat cells lit up brightly, meaning that HKU5 can easily infect them. However, human cells showed hardly any response unless the virus had certain mutations. The fear now is that if HKU5 jumps to an intermediate animal, for example a mink or civet, it could mutate enough before eventually reaching humans. One theory over the origins of the pandemic is that it was caused by a leak from a lab at the Wuhan Institute of Virology. This gained traction after the Director of the FBI Christopher Wray said the bureau believes Covid-19 "most likely" originated in a "Chinese government-controlled lab". However, last year scientists who were part of a major international study rejected this popular belief. They instead claimed that it broke out from a wet market in Wuhan, China. Genetic samples of animals that were sold at the market stalls in 2019 found traces of the Covid virus in some species. Author of the study, Kristian Andersen from Scripps Research, said in the document: "This adds another layer to the accumulating evidence that all points to the same scenario: that infected animals were introduced into the market in mid to late November 2019, which sparked the pandemic."
